Showing results (71-80 of 141) with videos related to

Sort By:
Pageof 15
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|July 1, 2011
Bortezomib for patients with advanced-stage bronchioloalveolar carcinoma: a California Cancer Consortium Phase II study (NCI 7003)Suresh S Ramalingam, Angela M Davies, Jeffrey Longmate, et al.
Cancer Chemotherapy and Pharmacology|February 14, 2013
A multi-histology trial of fostamatinib in patients with advanced colorectal, non-small cell lung, head and neck, thyroid, and renal cell carcinomas, and pheochromocytomasSook Ryun Park, Giovanna Speranza, Richard Piekarz, et al.
Molecular Cancer Therapeutics|February 16, 2018
Molecular Pharmacodynamics-Guided Scheduling of Biologically Effective Doses: A Drug Development Paradigm Applied to MET Tyrosine Kinase InhibitorsApurva K Srivastava, Melinda G Hollingshead, Jeevan Prasaad Govindharajulu, et al.
Cancer Chemotherapy and Pharmacology|June 10, 2006
A phase I and pharmacologic study of sequences of the proteasome inhibitor, bortezomib (PS-341, Velcade), in combination with paclitaxel and carboplatin in patients with advanced malignanciesCynthia Ma, Sumithra J Mandrekar, Steven R Alberts, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 13, 2009
Phase I study of vorinostat in combination with bortezomib for relapsed and refractory multiple myelomaAshraf Badros, Angelika M Burger, Sunita Philip, et al.
Investigational New Drugs|January 7, 2021
Phase II study of the histone deacetylase inhibitor vorinostat (Suberoylanilide Hydroxamic Acid; SAHA) in recurrent or metastatic transitional cell carcinoma of the urothelium - an NCI-CTEP sponsored: California Cancer Consortium trial, NCI 6879David I Quinn, Denice D Tsao-Wei, Przemyslaw Twardowski, et al.
The Oncologist|September 28, 2013
Phase II study of dasatinib (BMS-354825) in patients with metastatic adenocarcinoma of the pancreasCheng Ean Chee, Smitha Krishnamurthi, Charles J Nock, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 13, 2011
Evaluation of KRAS mutations, angiogenic biomarkers, and DCE-MRI in patients with advanced non-small-cell lung cancer receiving sorafenibRonan J Kelly, Arun Rajan, Jeremy Force, et al.
Cancer Chemotherapy and Pharmacology|September 24, 2009
A dose-finding and pharmacodynamic study of bortezomib in combination with weekly paclitaxel in patients with advanced solid tumorsBhuvaneswari Ramaswamy, Tanios Bekaii-Saab, Larry J Schaaf, et al.
Clinical Lung Cancer|January 29, 2011
Randomized phase II trial of concurrent versus sequential bortezomib plus docetaxel in advanced non-small-cell lung cancer: a California cancer consortium trialPrimo N Lara, Jeff Longmate, Karen Reckamp, et al.
Pageof 15